Tower Research Capital LLC TRC raised its stake in Humana Inc (NYSE:HUM) by 7,218.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,952 shares of the insurance provider’s stock after purchasing an additional 3,898 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Humana were worth $981,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in HUM. Advantus Capital Management Inc grew its stake in shares of Humana by 1.4% during the third quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock valued at $3,605,000 after acquiring an additional 203 shares in the last quarter. Cadence Capital Management LLC grew its stake in shares of Humana by 3.6% during the third quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock valued at $1,434,000 after acquiring an additional 205 shares in the last quarter. Daiwa SB Investments Ltd. grew its stake in shares of Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after acquiring an additional 220 shares in the last quarter. HL Financial Services LLC grew its stake in shares of Humana by 2.1% during the fourth quarter. HL Financial Services LLC now owns 11,205 shares of the insurance provider’s stock valued at $2,780,000 after acquiring an additional 230 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Humana by 3.6% during the third quarter. Mackenzie Financial Corp now owns 6,642 shares of the insurance provider’s stock valued at $1,618,000 after acquiring an additional 232 shares in the last quarter. 97.68% of the stock is currently owned by institutional investors.
Humana Inc (HUM) opened at $269.00 on Monday. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Humana Inc has a 52 week low of $203.36 and a 52 week high of $293.35. The company has a market capitalization of $37,037.08, a P/E ratio of 16.13, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.
Humana declared that its Board of Directors has approved a share buyback plan on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a $0.50 dividend. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date is Wednesday, March 28th. Humana’s payout ratio is presently 9.59%.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of Humana stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the transaction, the senior vice president now directly owns 9,888 shares in the company, valued at $2,432,151.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jody L. Bilney sold 7,054 shares of Humana stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the transaction, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,115 shares of company stock valued at $2,501,627. 0.80% of the stock is currently owned by insiders.
Several brokerages have recently weighed in on HUM. BMO Capital Markets raised their target price on Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Royal Bank of Canada restated a “sector perform” rating and set a $242.00 target price (down from $245.00) on shares of Humana in a research note on Thursday, November 9th. JPMorgan Chase & Co. raised their target price on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Finally, Morgan Stanley lowered their target price on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a research note on Thursday, November 9th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Humana currently has a consensus rating of “Buy” and an average target price of $270.47.
ILLEGAL ACTIVITY NOTICE: “Tower Research Capital LLC TRC Grows Holdings in Humana Inc (HUM)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/19/tower-research-capital-llc-trc-grows-holdings-in-humana-inc-hum.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.